# Grant McArthur

Source: https://onco.cc/people/mcarthur-grant/  
OnCo record `mcarthur-grant` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A melanoma pioneer who led the vemurafenib and cobimetinib trials and now heads Victoria's cancer alliance.

## Summary

Grant McArthur is Executive Director of the Victorian Comprehensive Cancer Centre Alliance and a melanoma medical oncologist at the Peter MacCallum Cancer Centre in Melbourne. He was a principal investigator for BRIM-3 and coBRIM, the trials that established BRAF inhibition with vemurafenib and combined BRAF and MEK inhibition with cobimetinib in melanoma. His publications include the extended follow-up of vemurafenib in BRAF V600E and V600K mutation-positive melanoma from BRIM-3. He has led translational programmes on resistance and on combining targeted therapy with immunotherapy, and now heads Victoria's cancer alliance.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Executive Director, Victorian Comprehensive Cancer Centre Alliance; melanoma medical oncologist, Peter Mac
- Specialisms: Melanoma; BRAF and MEK inhibitors; Immunotherapy; Translational research

## Sources

- Peter MacCallum Cancer Centre: https://www.petermac.org
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=McArthur%20GA%5BAuthor%5D%20melanoma

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- targets: [BRAF](https://onco.cc/targets/braf/)
- drugs: [Cobimetinib](https://onco.cc/drugs/cobimetinib/), [Vemurafenib](https://onco.cc/drugs/vemurafenib/)
- institutions: [Peter MacCallum Cancer Centre](https://onco.cc/institutions/peter-mac/)
- key papers: [CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma](https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/)

---
JSON: https://onco.cc/api/v1/entities/mcarthur-grant.json